Comorbidity: Substance Use Disorders and Other Psychiatric Conditions

摘要 简介：这是T32机构培训补助金申请的续签申请-科摩罗： 物质使用障碍和其他精神疾病（NIDA DA 037183）-在完成其 第一个五年筹资周期。在目前NIDA资助的培训赠款组合中，只有一个项目 除了我们的（达特茅斯）有comorbance作为一个主要的焦点。这是惊人的同时发生 物质使用障碍（SUD）与其他精神疾病和健康状况（例如， 糖尿病），以及SUD或共病疾病在多大程度上可以进行治疗或未治疗， 常规治疗设置。更新计划的目标、要素和资源保留了关键和 这将有助于提高初始供资期的有效要素，同时纳入重要的经验教训。长期目标： 拟议的方案将培养一批具有共同机制研究专长的科学家， 前因和相关因素、诊断以及心理社会和药物干预。组件 目标是使每个受训者掌握科摩罗研究的工作知识，包括： 从早期临床试验到基于社区的前瞻性研究的转化科学 （B）针对不同人群和种族共病状况的有效研究策略， 文化群体（如美洲印第安人、苗族、索马里人）。实现程序化功能将利用 (a)教师专业知识的范围，提供跨多个领域的指导，以及（B）跨 培训计划和部门。关键要素：（1）科学家和临床医生的参与， 专业知识和核心内部咨询小组。主要研究中心（4名博士后培训生，每人2年）是 精神病学和心理学（UMN双城）和家庭医学和生物行为健康部门 (UMN杜卢斯）;（2）征聘经过严格筛选的博士和 以SUD和科摩罗为主要职业重点的MD候选人;（3）跨学科培训 导师团队（初级导师和2名中级导师），具有互补的专业知识;（4）正式的培训计划， 明确的里程碑，包括第一年开始的NIH应用程序的受训者开发;（5）积极的研究， 研讨会，教学课程，讲习班，以及管理，道德和监管的发展 专业知识;（6）动态的程序管理，包括监控、增强和问题解决 沿着继续与学员接触，并在完成培训后;（7）每年召开外部咨询会议 组资源：导师资金来源包括NIH研究所，NSF，明尼苏达医学基金会， 医药行业。关键人员和主要导师是诊所、中心或部门的主管 拥有大量资源。

Abstract Introduction: This is a renewal application for T32 institutional training grant application – Comorbidity: Substance Use Disorders and Other Psychiatric Conditions (NIDA DA037183) -- following the completion of its first five-year funding cycle. Among the current portfolio of NIDA funded training grants, only one program other than ours (Dartmouth) has comorbidity as a primary focus. This is striking given co-occurrence prevalence of Substance Use Disorders (SUD) with other psychiatric conditions and health conditions (e.g. diabetes), and the extent to which either SUD or the comorbid disorder can go under- or untreated in conventional treatment settings. The goals, elements and resources of the renewal program retains critical and effective elements of the initial funding period while incorporating important lessons learned. Long term goals: The proposed program will develop a cadre of scientists with research expertise in comorbidity mechanisms, antecedents and correlates, diagnostics, and psychosocial and pharmacological interventions. Component objectives are to provide each trainee with a working knowledge of comorbidity research including: (a) translational science from Early Phase Clinical Trials to Community Based Participatory Research perspectives; (b) effective research strategies for comorbid conditions across populations and ethnic and cultural groups (e.g. American Indian, Hmong, Somali). Accomplishing programmatic features will capitalize on (a) the spectrum of faculty expertise providing mentoring across multiple areas, and (b) integration across training programs and departments. Key Elements: (1) Involvement of scientists and clinicians with diverse expertise and a core internal advisory group. Primary sites (4 postdoctoral trainees, 2 yrs each) are the Departments of Psychiatry and Psychology (UMN Twin Cities) and Family Medicine and Biobehavioral Health (UMN Duluth); (2) Recruitment, including under represented group outreach, of rigorously screened PhD and MD candidates with SUD and comorbidity as primary career focus; (3) Training with an interdisciplinary mentoring team (primary & 2 secondary mentors) with complementary expertise; (4) Formal training plans with clear milestones including trainee development of an NIH application initiated in Year 1; (5) Active research, seminars, didactic course work, workshops, and development of management, ethics, and regulatory expertise; (6) Dynamic program administration entailing monitoring with enhancements and problem resolution along with continued contact with trainees after completion and; (7) Annually convened external advisory group. Resources: Mentor funding sources include NIH Institutes, NSF, Minnesota Medical Foundation, and pharmaceutical industry. Key Personnel and Primary Mentors are directors of clinics, centers, or departments with significant resources.